Acoustic rhinometry in the dog: a novel large animal model for studies of nasal congestion.
The aim of this project was to develop and pharmacologically characterize an experimental dog model of nasal congestion in which nasal patency is measured using acoustic rhinometry. Solubilized compound 48/80 (0.3-3.0%) was administered intranasally to thiopental anesthetized beagle dogs to elicit nasal congestion via localized mast cell degranulation. Compound 48/80-induced effects on parameters of nasal patency were studied in vehicle-treated animals, as well as in the same animals pretreated 2 hours earlier with oral d-pseudoephedrine or chlorpheniramine. Local mast cell degranulation caused a close-related decrease in nasal cavity volume and minimal cross-sectional area (Amin) together with a highly variable increase in nasal secretions. Maximal responses were seen at 90-120 minutes after 48/80 administration. Oral administration of the adrenergic agonist, d-pseudoephedrine (3.0 mg/kg), significantly antagonized all of the nasal effects of compound 48/80 (3.0%). In contrast, oral administration of the histamine H1 receptor antagonist chlorpheniramine (10 mg/kg) appeared to reduce the increased nasal secretions but was without effect on the compound 48/ 80-induced nasal congestion (i.e., volume and Amin). These results show the effectiveness of using acoustic rhinometry in this anesthetized dog model. The observations that compound 48/80-induced nasal congestion was prevented by d-pseudoephedrine pretreatment, but not by chlorpheniramine, suggest that this noninvasive model system may provide an effective tool with which to study the actions of decongestant drugs in preclinical investigations.
Koss
Michael C
MC
Department of Cell Biology, University of Oklahoma, College of Medicine, Oklahoma City 73190, USA.
Yu
Yongxin
Y
Hey
John A
JA
McLeod
Robbie L
RL
D000162:Acoustics; D000403:Airway Resistance / Q000187:drug effects; D000818:Animals; D002744:Chlorpheniramine / Q000494:pharmacology*; D004195:Disease Models, Animal; D004285:Dogs; D004347:Drug Interactions; D004809:Ephedrine / Q000494:pharmacology*; D008297:Male; D015508:Nasal Obstruction / Q000175:diagnosis* / Q000188:drug therapy*; D010036:Otolaryngology / Q000379:methods*; D011336:Probability; D012016:Reference Values; D012680:Sensitivity and Specificity
D002744:Chlorpheniramine; D004809:Ephedrine